Santaris Pharma, a privately held clinical-stage biopharmaceutical company, utilizes its proprietary LNA chemistry and specialized drug development capabilities to rapidly deliver potent single-stranded LNA-based drug candidates across various disease states. Their research and development efforts concentrate on infectious diseases and cardiometabolic disorders, while strategic partnerships with leading pharmaceutical companies cover therapeutic areas such as cancer, cardiovascular disease, infectious and inflammatory diseases, and rare genetic disorders. With exclusive worldwide rights to manufacture and sell LNA-containing products, Santaris Pharma has established itself as a key player in the RNA-targeted therapy field. Founded in 2003 and headquartered in Denmark, the company operates in the United States as well.